Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Mafosfamide enhances interleukin-2-generated human effector cell cytotoxic activity against K562 myeloid leukaemia cells.

Literature DB >> 7633833

Mafosfamide enhances interleukin-2-generated human effector cell cytotoxic activity against K562 myeloid leukaemia cells.

H T Hassan¹.

Abstract

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 1994 PMID： 7633833 DOI： 10.1007/bf02999862

Source DB: PubMed Journal: Med Oncol ISSN： 1357-0560 Impact factor: 3.064

Keyword Cloud
References

× No keyword cloud information.

12 in total

1. Influence of low doses of an oxazaphosphorine on natural killer activity of human lymphocytes.

Authors: H Blomgren
Journal: Cancer Immunol Immunother Date: 1989 Impact factor: 6.968

2. Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 in disseminated melanoma [corrected].

Authors: M S Mitchell; R A Kempf; W Harel; H Shau; W D Boswell; S Lind; E C Bradley
Journal: J Clin Oncol Date: 1988-03 Impact factor: 44.544

3. Hematologic and immunologic effects of the systemic administration of recombinant interleukin-2 after autologous bone marrow transplantation.

Authors: D Blaise; D Olive; A M Stoppa; P Viens; C Pourreau; M Lopez; M Attal; C Jasmin; G Monges; C Mawas
Journal: Blood Date: 1990-09-15 Impact factor: 22.113

4. Autologous marrow transplantation in acute lymphoblastic leukemia: control of residual disease with mafosfamide and induction of syngeneic GVHD with cyclosporin. The Italian Mafosfamide Study Group.

Authors: V Rizzoli; A M Carella; C Carlo-Stella; L Mangoni
Journal: Bone Marrow Transplant Date: 1990-07 Impact factor: 5.483

5. Synergistic interactions between differentiation-inducing agents in inhibiting the proliferation of HL-60 human myeloid leukaemia cells in clonogenic micro assays.

Authors: H T Hassan; A Veit; H R Maurer
Journal: J Cancer Res Clin Oncol Date: 1991 Impact factor: 4.553

10. Interleukin 2 prevents graft-versus-host disease while preserving the graft-versus-leukemia effect of allogeneic T cells.

Authors: M Sykes; M L Romick; D H Sachs
Journal: Proc Natl Acad Sci U S A Date: 1990-08 Impact factor: 11.205

Mafosfamide enhances interleukin-2-generated human effector cell cytotoxic activity against K562 myeloid leukaemia cells.

1. Influence of low doses of an oxazaphosphorine on natural killer activity of human lymphocytes.

2. Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 in disseminated melanoma [corrected].

3. Hematologic and immunologic effects of the systemic administration of recombinant interleukin-2 after autologous bone marrow transplantation.

4. Autologous marrow transplantation in acute lymphoblastic leukemia: control of residual disease with mafosfamide and induction of syngeneic GVHD with cyclosporin. The Italian Mafosfamide Study Group.

5. Synergistic interactions between differentiation-inducing agents in inhibiting the proliferation of HL-60 human myeloid leukaemia cells in clonogenic micro assays.

Review 6. Agar capillary clonogenic microassays for cellular immunocytotoxic activities in human leukaemia and lymphoma.

7. Augmentation of host antitumor immunity by low doses of cyclophosphamide and mafosfamide in two animal tumor models.

8. Lymphokine-activated killer (LAK) cell purging of bone marrow.

9. Pharmacological-mediated purging with mafosfamide in acute and chronic myeloid leukemias. The Italian Study Group.

10. Interleukin 2 prevents graft-versus-host disease while preserving the graft-versus-leukemia effect of allogeneic T cells.